Browsing Tag
Imviva Biotech
2 posts
A one-time lupus reset? Why CTA313 is forcing competitors to rethink strategy
Can CTA313 disrupt lupus markets with one-time remission? Explore how Imviva Biotech is reshaping autoimmune competition.
Orphan drug designation for CTD402 raises stakes for allogeneic CAR-T in relapsed T-cell leukemia
CTD402 secures FDA orphan designation. Read how this raises execution stakes for allogeneic CAR-T in relapsed T-cell leukemia.